Milestone prediction for time-to-event endpoint monitoring in clinical trials

被引:1
|
作者
Ou, Fang-Shu [1 ]
Heller, Martin
Shi, Qian [1 ]
机构
[1] Mayo Clin, Dept Hlth Sci Res, Canc Ctr, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
clinical trial; density forecast combination; event modeling; model stacking; prediction synthesis; trial monitoring; FLUOROURACIL; RECRUITMENT; OXALIPLATIN; LEUCOVORIN; ENROLLMENT; STACKING; COUNTS;
D O I
10.1002/pst.1934
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Predicting the times of milestone events, ie, interim and final analyses in clinical trials, helps resource planning. This manuscript presents and compares several easily implemented methods for predicting when a milestone event is achieved. We show that it is beneficial to combine the predictions from different models to craft a better predictor through prediction synthesis. Furthermore, a Bayesian approach provides a better measure of the uncertainty involved in prediction of milestone events. We compare the methods through two simulations where the model has been correctly specified and where the models are a mixture of three incorrectly specified model classes. We then apply the methods on two real clinical trial data, North Central Cancer Treatment Group (NCCTG) N0147 and N9841. In summary, the Bayesian prediction synthesis methods automatically perform well even when the data collection is far from homogeneous. An R shiny app is under development to carry out the prediction in a user-friendly fashion.
引用
收藏
页码:433 / 446
页数:14
相关论文
共 50 条
  • [1] Predicting study duration in clinical trials with a time-to-event endpoint
    Machida, Ryunosuke
    Fujii, Yosuke
    Sozu, Takashi
    [J]. STATISTICS IN MEDICINE, 2021, 40 (10) : 2413 - 2421
  • [2] Consideration of stratification in confirmatory trials with time-to-event endpoint
    Wang, Yizhuo
    Zhou, Xuan
    Guo, Zifang
    Fang, Xiao
    Liu, Fang
    Shen, Liji
    [J]. CONTEMPORARY CLINICAL TRIALS, 2024, 141
  • [3] A Bayesian adaptive design for biosimilar trials with time-to-event endpoint
    Belay, Sheferaw Y.
    Mu, Rongji
    Xu, Jin
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (03) : 597 - 609
  • [4] Real time monitoring and prediction of time to endpoint maturation in clinical trials
    Wang, Li
    Liu, Yang
    Chen, Xiaotian
    Pulkstenis, Erik
    [J]. STATISTICS IN MEDICINE, 2022, 41 (18) : 3596 - 3611
  • [5] Group sequential testing for cluster randomized trials with time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    [J]. BIOMETRICS, 2022, 78 (04) : 1353 - 1364
  • [6] Sample size calculation for cluster randomization trials with a time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    [J]. STATISTICS IN MEDICINE, 2020, 39 (25) : 3608 - 3623
  • [7] Development of a time-to-event endpoint for use in premanifest Huntington's disease (HD) clinical trials
    Rossomanno, S.
    Guthrie, H.
    Wild, E. J.
    Schobel, S. A.
    Boak, L.
    Trundell, D.
    [J]. MOVEMENT DISORDERS, 2020, 35 : S102 - S102
  • [8] Comparison of Time-to-Event Data for Clinical Trials
    Nadarajah, Saralees
    [J]. MONTE CARLO METHODS AND APPLICATIONS, 2007, 13 (01): : 21 - 35
  • [9] Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions
    Rufibach, Kaspar
    Grinsted, Lynda
    Li, Jiang
    Weber, Hans Jochen
    Zheng, Cheng
    Zhou, Jiangxiu
    [J]. PHARMACEUTICAL STATISTICS, 2023, 22 (04) : 671 - 691
  • [10] Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
    McCaw, Zachary R.
    Kim, Dae Hyun
    Wei, Lee-Jen
    [J]. JNCI CANCER SPECTRUM, 2022, 6 (01)